- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00289341
Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells.
A Phase I/II Study of Autologous Dendritic Cells Pulsed With Apoptotic Tumor Cells (DC/LNCaP) Administered Subcutaneously to Prostate Cancer Patients.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
New York
-
New York, New York, Stati Uniti, 10021
- Rockefeller University Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
Disease Characteristics
- Histologically confirmed prostate carcinoma
- Progressive, disease required, i.e.: elevated PSA documented to be rising on 3 occasions, either despite castrate testosterone levels (below 50 ng/dl), or after definitive local therapy (prostatectomy or radiation).
Prior/Concurrent Therapy
-Biologic therapy:
Recovered from toxicity of any prior therapy
-Chemotherapy:
- At least 4 weeks since chemotherapy -Endocrine evaluation/therapy
- 3 rising PSA values at least 2 weeks apart
- At least 2 weeks since concurrent corticosteroids (other than for replacement therapy for adrenal insufficiency)
Medical hormonal therapy to maintain castrate testosterone levels permitted
-Radiotherapy:
At least 4 weeks since radiotherapy
-Surgery:
- Prior surgery allowed
Patient Characteristics
- Age: 18 and over, able to give written informed consent. Individuals unable to provide informed consent must have consent provided by the legal guardian, or person designated by the subject to give consent on his behalf.
- Performance status: Karnofsky 70-100%
- Life expectancy: At least 1 year
- Hematopoietic: obtained twice, once within 45 days prior to study entry, and again within 72 hours of study entry.
- WBC greater than 3,800
- Absolute neutrophils greater than 1,500
- Absolute lymphocytes greater than 500
- Platelets greater than 120,000
- Hb at least 10 g/dl
Hepatic:
--Bilirubin less than 2.0 mg/dl OR
--SGOT less than 2 x ULN
Renal:
- Creatinine no greater than 2.0 mg/dl OR
- Creatinine clearance at least 40 ml/min
Rheumatologic:
--ANA no greater than upper limit of normal, or ANA abnormal in absence of clinical signs of autoimmunity.
- Rheumatoid factor (RF) no greater than upper limit of normal, or RF abnormal in absence of clinical signs of autoimmunity.
- Anti-ds DNA no greater than upper limit of normal, or anti ds DNA abnormal in absence of clinical signs of autoimmunity.
- Immunologic:
- Influenza serology (assessment made at time of screening).
- Assessment of DTH response to a standard anergy panel (to include candida, trichophyton and tetanus) or to a Multitest CMI (a disposable kit for DTH testing with standardized preloaded antigens).
Endocrine:
--TSH, T3, and T4 no greater than upper limit of normal
Radiographic:
- Baseline bone scan
- Baseline CT or MRI of abdomen and pelvis
Exclusion Criteria:
Disease Characteristics -No active CNS metastases
Prior/Concurrent Therapy
Biologic therapy:
- No prior autologous or allogeneic tumor vaccines
- No concurrent other immunotherapy
Chemotherapy
--Not previously treated with more than 2 chemotherapy regimens
- No concurrent chemotherapy
- Radiotherapy --No concurrent radiotherapy
Patient Characteristics -Cardiovascular: No NYHA class III/IV status No active angina, clinically significant cardiac arrythmia, recent (6 months) myocardial infarction
Pulmonary:
--No severe debilitating pulmonary disease
Other:
- No active infection requiring antibiotics
- No active pain requiring chronic opioid analgesics.
- Not HIV, hepatitis B or hepatitis C virus positive; anti-HIV, HbsAg and Hep C antibody negative
- No history of hypersensitivity to vaccine components
- No serious uncontrolled medical illness
- No currently active second malignancy other than non-melanoma skin cancer (note: a patient is NOT considered to have currently active malignancy if they have completed therapy and are now considered by their physician to be at less than 30% risk for relapse)
- No history of total lymph node irradiation
- No history of vasculitis, including but not limited to systemic necrotizing vasculitides (polyarteritis nodosa group), hypersensitivity vasculitis, Wegener's granulomatosis.
- No history of autoimmune disease.
- No use of hydroxyurea within 45 days of study entry
- No receipt of immune modulators or suppressors within 30 days prior to study entry, including but not limited to interferons and thalidomide. No active requirement for corticosteroids; prior use is acceptable.
- No psychiatric illness or social condition that, in the opinion of the investigator, would interfere with adherence to study requirements.
- No alcohol or drug use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Comparatore placebo: Placebo
12 patients in the placebo Arm for 8 weeks followed by DC/LNCAP, DC/LNCaP-M1 and DC/KLH immunizations over 8 weeks.
|
Subcutaneous injection of vaccine vehicle only (5% DMSO in normal saline), followed by cross-over to Arm 1 design.
|
Sperimentale: DC/LNCaP
12 patients, receiving DC/LNCaP, DC/LNCaP-M1 and DC/KLH immunizations over 8 weeks
|
Subcutaneous injection of DC/LNCaP, DC/LNCaP-M1, DC/KLH
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Adverse Event
Lasso di tempo: End of blinded phase (wk 9)
|
Occurrence of adverse events (AE) was compared between the placebo and vaccine groups during the blinded phase (the 1st 9 weeks).
At the end of this phase, all were unblinded, and those who received placebo crossed over to now receive vaccine.
All serious AEs and any other AEs that occurred 5 times or more are reported.
The exact binomial test was used to compare the occurrence of each AE between groups.
|
End of blinded phase (wk 9)
|
Immunogenicity of the DC/LNCaP Vaccine. Pre- vs Post-vaccination Bulk T Cell Proliferation (3H Thymidine Incorporation) by Type of Antigen. The "Number" Indicated is the Median Difference of Post-Pre, of Each Antigen Group.
Lasso di tempo: pre- vs post-vaccination. Pre-vaccination T cells were collected at Wk 0 and post-vaccination T cells were collected at Wk 13
|
The difference between post minus pre-vaccination bulk T cell proliferation was calculated for each antigen.
|
pre- vs post-vaccination. Pre-vaccination T cells were collected at Wk 0 and post-vaccination T cells were collected at Wk 13
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Change in PSA Slope, Pre- vs Post-vaccination.
Lasso di tempo: pre- vs post- vaccination PSA slopes.
|
To model the evolution of PSA (in log-scale) during the three study phases (pre-vaccine, vaccine, and post-vaccine phases), a mixed linear spline model was used.
Two knots (one at the start of the vaccine phase and the other at the start of the post-vaccine phase) were used to directly quantify the differences in slopes between each phase.
To account for the heterogeneous treatment effect and the repeated measures structure, random effects are incorporated into the model.
For the general model, random effects for the intercept, slope and the first knot were considered.
|
pre- vs post- vaccination PSA slopes.
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Robert B. Darnell, MD, PHD, Rockefeller University
Pubblicazioni e link utili
Pubblicazioni generali
- Frank MO, Kaufman J, Parveen S, Blachere NE, Orange DE, Darnell RB. Dendritic cell vaccines containing lymphocytes produce improved immunogenicity in patients with cancer. J Transl Med. 2014 Dec 5;12:338. doi: 10.1186/s12967-014-0338-3.
- Frank MO, Kaufman J, Tian S, Suarez-Farinas M, Parveen S, Blachere NE, Morris MJ, Slovin S, Scher HI, Albert ML, Darnell RB. Harnessing naturally occurring tumor immunity: a clinical vaccine trial in prostate cancer. PLoS One. 2010 Sep 1;5(9):e12367. doi: 10.1371/journal.pone.0012367.
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- RDA 0466
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cancro alla prostata
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletatoAdenocarcinoma dell'intestino tenue | Adenocarcinoma dell'intestino tenue in stadio III AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIA AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIB AJCC v8 | Adenocarcinoma dell'intestino tenue stadio IV AJCC v8 | Ampolla di Vater... e altre condizioniStati Uniti
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...CompletatoStudio delle donne cinesi che non hanno aderito alle linee guida per lo screening mammografico dell'American Cancer SocietyStati Uniti
-
National Cancer Institute (NCI)ReclutamentoKita-kyushu Lung Cancer Antigen 1, umanoStati Uniti
-
Novartis PharmaceuticalsReclutamentoEGFR mutante avanzato Non SmallSellLung Cancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal SquamousCell Cancer (SCC), Head/Neck SCC, MelanomaOlanda, Corea, Repubblica di, Spagna, Taiwan, Giappone, Italia, Canada, Stati Uniti, Singapore
-
Emory UniversityNational Cancer Institute (NCI)RitiratoCancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nel cervello | Carcinoma mammario metastatico | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Attivo, non reclutanteCancro al seno in stadio anatomico IV AJCC v8 | Cancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nell'osso | Neoplasia maligna metastatica nei linfonodi | Neoplasia maligna metastatica nel fegato | Carcinoma mammario metastatico | Neoplasia maligna metastatica nel... e altre condizioniStati Uniti, Canada, Arabia Saudita, Corea, Repubblica di
-
Jonsson Comprehensive Cancer CenterNon ancora reclutamentoCarcinoma della prostata | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Rashmi Verma, MDNational Cancer Institute (NCI)ReclutamentoCarcinoma prostatico resistente alla castrazione | Adenocarcinoma prostatico metastatico | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Assiut UniversityNon ancora reclutamentoDeterminare l’incidenza cumulativa di AKI utilizzando i criteri KDIGO in pazienti pediatrici con tumori maligni presso il South Egypt Cancer Institute (SECI)
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Attivo, non reclutanteStadio III Adenocarcinoma della prostata AJCC v7 | Stadio II Adenocarcinoma prostatico AJCC v7 | Fase I Adenocarcinoma della prostata American Joint Committee on Cancer (AJCC) v7Stati Uniti
Prove cliniche su vaccine vehicle only
-
Boston UniversityNational Cancer Institute (NCI); Brown University; National Institutes of Health... e altri collaboratoriCompletato
-
The University of Texas Health Science Center,...Completato
-
TASK Applied ScienceCompletatoCOVID-19 | SARS-CoV-2Sud Africa
-
AtaCor Medical, Inc.CompletatoDifetto di conduzioneNuova Zelanda, Paraguay